Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience

Article Medicine, General & Internal

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia

Pau Montesinos et al.

Summary: This study demonstrated that the combination therapy of oral ivosidenib and azacitidine showed better event-free survival and longer overall survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

添加到收藏夹

Article Hematology

Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment

Firas Kreidieh et al.

Summary: This article provides an overview of prevention and treatment of relapse in patients with acute myeloid leukemia (AML) post-allogeneic hematopoietic stem cell transplantation (allo-HSCT), including cell-based and pharmacologic options. The effectiveness of post-transplant maintenance therapy, pre-emptive treatment, and prophylactic donor lymphocyte infusion (DLI) in preventing relapse is discussed. Targeted post-transplant pharmacological interventions and the potential role of CAR-T cells in AML are also mentioned.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Oncology

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

Naval Daver et al.

Summary: Combining gilteritinib with venetoclax has shown promising results in treating relapsed/refractory FLT3-mutated AML, with high rates of response and molecular remission regardless of prior FLT3 inhibitor therapy.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Meeting Abstract Hematology

In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Matthias Stelljes et al.

BLOOD (2022)

添加到收藏夹

Article Oncology

Impact of disease status at allogeneic stem cell transplantation on adolescent and young adult patients with early T-cell precursor acute lymphoblastic leukemia

Tongyan Meng et al.

Summary: This retrospective analysis of 30 AYA patients with ETP-ALL who underwent allo-HSCT showed that disease status prior to transplant significantly impacted overall survival rates. Patients transplanted in CR1/2 had better outcomes compared to those with active disease, highlighting the importance of disease status in predicting survival outcomes.

HEMATOLOGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology